Bolt Biotherapeutics Announces Clinical Collaboration with Bristol Myers Squibb to Study ...

Retrieved on: 2021-09-08 11:26:15

Tags for this article:

Clinical medicine

Medicine

Health care

Immune system

Clusters of differentiation

Antineoplastic drugs

Cancer immunotherapy

Immunology

Programmed cell death protein 1

Checkpoint inhibitor

Tumor microenvironment

HER2/neu

Bolt Biotherapeutics, Inc.

Bristol-Myers Squibb Company

Bristol-Myers Squibb

Click the tags to see associated articles and topics

Bolt Biotherapeutics Announces Clinical Collaboration with Bristol Myers Squibb to Study .... View article details on HISWAI: https://www.biospace.com/article/releases/bolt-biotherapeutics-announces-clinical-collaboration-with-bristol-myers-squibb-to-study-bdc-1001-in-combination-with-opdivo-for-treatment-of-her2-expressing-solid-tumors/

Excerpt

... a clinical-stage biotechnology company pioneering a new class of ... antibodies with the power of both the innate and adaptive immune systems, ...

Article found on: www.biospace.com

View Original Article